Bronchoalveolar lavage neutrophilia in acute lung allograft rejection and lymphocytic bronchiolitis by Vos, Robin et al.
Broncho-alveolar lavage in acute rejection and lymphocytic bronchiolitis after lung transplantation:  
is neutrophilia a paradox or opportunity for tailored treatment? 
 
Robin Vos
1
 (MD), Bart M. Vanaudenaerde
1
 (PhD), Stijn E. Verleden
1
, Stéphanie I. De 
Vleeschauwer
1
, Anna Willems-Widyastuti
1
, Dirk E. Van Raemdonck
2,3
 (MD, PhD), Lieven J. 
Dupont
1,3
 (MD, PhD), Erik K. Verbeken
4
 (MD, PhD) and Geert M. Verleden
1,3 
(MD, PhD). 
 
1 
Laboratory of Pneumology, 
2 
Laboratory of Experimental Thoracic Surgery,  
3 
Lung Transplantation Unit and 
4
 Department of Histology,
 
Katholieke Universiteit Leuven and University Hospital Gasthuisberg, Leuven, Belgium. 
 
 
Running title: Airway lavage and biopsy in lung rejection 
 
Keywords: acute rejection, biopsy, broncho-alveolar lavage, lung transplantation, lymphocytic 
bronchiolitis 
 
Word count: - abstract:   197  Tables: 4  References: 25  
  - body of text: 3394  Figures: 3 
Online supplement: 1 figure with legend (237 words) for Wiley-Blackwell hosting. 
 
Grants: Research Foundation-Flanders (G.0518.06, G.0643.08) and GSK Belgium. RV is a 
research fellow and BMV, DEVR and LJD senior research fellows of the FWO. GMV is holder 
of the GSK Chair in respiratory pharmacology at the KUL, Belgium.  
 
Conflict of interest statement: None of the authors has a financial relationship with a 
commercial entity that has an interest in the subject of the presented manuscript.  
 
 
 
Address for correspondence: Prof. Dr. G. Verleden  
University Hospital Gasthuisberg 
Lung Transplantation Unit 
49 Herestraat, B-3000 Leuven, Belgium 
   Tel: + 32 16 346800 Fax: + 32 16 346803 
   E-mail: geert.verleden@uz.kuleuven.be 
 
 
 1 
Abstract 
 
 Acute cellular rejection (grade A) and lymphocytic bronchiolitis (grade B) may impair 
allograft function after lung transplantation (LTx).  
 We investigated broncho-alveolar lavage (BAL) cellular and protein profiles for different 
grade A or B severity scores, hypothesizing that concurrent BAL neutrophilia might favor 
azithromycin-use in either condition.  
 All consecutive BAL with subsequent transbronchial biopsies (TBB), performed in 339 
LTx recipients from 2001 to 2008, were retrospectively analyzed. TBB were classified according 
to histological grade and compared for BAL cell differentials and IL-6/IL-8/TGF-β protein levels. 
We included 768 TBB for analysis and excluded 64 TBB with histological signs of 
infection. BAL total cell count significantly increased with grade A or B severity. A higher A 
grade was associated with a significant increase in lymphocytosis and to a lesser extent 
neutrophilia, whereas for higher B grades increased neutrophilia was present. IL-8 levels 
similarly were associated with grade A or B severity. A similar trend was seen for IL-6 with 
grade A and TGF-ß with grade B severity.  
A distinct BAL profile is present with increasing grade A or B severity. Especially B grades 
are characterized by increased BAL neutrophilia; azithromycin therapy might thus be beneficial, 
which warrants further prospective investigation. 
 
 
 
 
 
 
 
Abstract word count: 197        Keywords: acute rejection, biopsy, broncho-alveolar lavage, lung transplantation, lymphocytic bronchiolitis. 
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Introduction 
Acute cellular rejection (AR, grade A) and lymphocytic bronchiolitis (LB, grade B) are 
major histological risk factors for bronchiolitis obliterans syndrome (BOS) and mortality after 
lung transplantation (LTx) (1-4). Fiber-optic bronchoscopy with transbronchial lung biopsies 
(TBB) remains the gold standard for diagnosis and both conditions are histologically graded 
according to intensity and distribution of mononuclear cellular infiltrates, either perivascular and 
interstitial (A0-none, A1-minimal, A2-mild, A3-moderate, A4-severe), or submucosal (B0-none, 
B1R (previous B1 and B2)-low grade, B2R (previous B3 and B4)-high grade, BX-upgradeable) 
(2). In higher A and B-grades (A3/4, B2R) some neutrophils may be present within the biopsy 
specimen, yet the presence of a disproportionate number of neutrophils in relation to 
mononuclear cells is highly suggestive of infection rather than rejection (2). Concurrent LB may 
be seen in association with AR grade A2 or greater, but is less common with minimal (grade A1) 
AR (2). Nevertheless, it has only recently been recognized that LB may have similar implications 
as AR for allograft function and the appearance of obliterative bronchiolitis (OB) after LTx (3;4). 
Treatment options for both AR and LB predominantly consist of high-dose systemic steroids, 
often in association with modifying the immunosuppressive regimen, however addition of inhaled 
steroids may also be beneficial in LB (5). Although broncho-alveolar lavage (BAL) fluid in AR 
has previously been shown to be characterized by marked (predominantly CD8
+
) lymphocytosis 
(6-8), only very few studies actually correlated BAL findings with AR and/or LB-severity (8;9). 
Furthermore, during the past years novel anti-inflammatory and anti-oxidative drugs, such as 
azithromycin, have been introduced in the field of LTx, yet its potential benefit in AR or LB has 
thus far never been investigated.  
The aim of the present study was therefore to investigate BAL cellular and protein profiles 
of particular pro-inflammatory cyto-/chemokines and remodeling factors (IL-6, IL-8, TGF-ß) in 
different AR or LB severity grades, as we hypothesized that there may be a discrepancy between 
AR and LB or different grades (particularly considering BAL neutrophilia), which could possibly 
favor response to azithromycin therapy in these conditions. 
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Materials and methods 
Study design and population  
The study comprises a retrospective analysis of all surveillance or clinically indicated 
consecutive bronchoscopic procedures with BAL and TBB, performed between Oct. 2001 and 
Oct. 2008, in a cohort of 339 LTx recipients (transplanted from Aug. 1991 to Sept. 2008). The 
evaluation was restricted to this 7-year period because since Oct. 2001 all LTx recipients are 
enrolled in a prospective bronchoscopic routine follow-up program in our center and because 
throughout the subsequent years the revised 1996 International Society for Heart and Lung 
Transplantation (ISHLT) classification for TBB was uniformly applied (10). The study was 
approved by the local University Hospital Ethical Review Board and all patients gave written 
informed consent. 
Bronchoscopy with BAL and/or TBB 
Bronchoscopic procedures, for microbiological and virological assessment, quantification 
of cell differentials and protein levels and/or histology, were performed as previously described 
(11). Briefly, BAL was routinely carried out around fixed time points after LTx (21, 90, 180, 360, 
540, 720, 900, 1080, 1260, 1440, etc. days), or if AR, infection or BOS was clinically suspected. 
Likewise, surveillance TBB was routinely performed at days 21 and 90 post-LTx, thereafter in 
case of clinical suspicion of AR, infection or BOS.  
BAL was performed in a subsegmental bronchus of the right middle lobe (bilateral or right 
single LTx) or lingula (left single LTx) with two 50 mL aliquots of sterile saline at room 
temperature. After each instillation, BAL fluid was recovered by manual suction and fractions 
were pooled for analysis. Subsequently, TBB were performed as outlined in the revised ISHLT 
guidelines (2) in right middle and/or lower lobe or left lower lobe if indicated.  
Five mL of the BAL fluid was sent for microbiological and virological assessment, whereas 
the remaining fluid was immediately transported to the lab for further analysis, blinded to the 
patient’s clinical status. A cytospin was made with 105 cells/mL in a Shandon cytocentrifuge 
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(Techgen, Zellik, Belgium) and stained with May-Grünwald-Giemsa. Differential cell counts 
were determined by counting at least 300 cells. If lymphocytosis was above 10%, lymphocyte 
sub-types (CD19+ B and CD3+T-cells with CD4+ and CD8+ count) were additionally analyzed 
using flow-cytometric analysis (monoclonal antibodies and FACSCanto, Becton Dickinson, 
Erembodegem, Belgium). BAL protein levels of IL-6, IL-8 and TGF-β were analyzed in 
duplicate in 100 µl undiluted BAL supernatant using commercially available sandwich enzyme-
linked immunosorbent assays (ELISA) (Invitrogen, Merelbeke, Belgium). If the concentration 
was below the detection limit (respectively 0.2, 1 and 5 pg/mL), a value of half this limit was 
accorded for analysis.  
TBB specimens were fixed in formalin, embedded into a paraffin block and subsequently 5 
µm histological sections were obtained by serial cutting at two levels and immunohistochemical 
staining (Hematoxylin-Eosin as well as Gram staining and if indicated staining for 
cytomegalovirus (CMV), Herpes, Pneumocystis, as well as Verhoeff’s Elastica, Ziehl-Neelson 
and/or Grocott staining) according to standard criteria. All TBB specimens were examined by a 
single pathologist (EKV) skilled in LTx, who was blinded to the patients’ clinical status; and 
graded according to the 1996 ISHLT guidelines (grade A0-4 with concomitant B0-4) (10). ‘Bx’ 
biopsies were evaluable for A grading, but did not show bronchiolar epithelium to allow a B 
grade to be determined. Similarly, biopsies with bronchiolar tissue, but no or insufficient 
alveolated lung parenchyma, were classified as ‘Ax’ for the current study. ‘Inadequate’ biopsies 
(AxBx) did neither show adequate bronchiolar epithelium nor sufficient alveolar tissue for A or B 
grading, or demonstrated other interstitial lesions of the pulmonary graft (e.g. bronchiolitis 
obliterans organising pneumonia (BOOP), diffuse alveolar damage (DAD), interstitial 
pneumonitis). For the current study, TBB were classified according to A and/or B grade and 
subsequently compared for demographical and BAL characteristics.  
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Assessment of pulmonary function 
Spirometry was performed in agreement with American Thoracic Society (ATS)-criteria 
prior to bronchoscopy (Masterscreen, Jaeger, Hoechberg, Germany) (12).  
Immunosuppressive and prophylactic regimen 
Conventional post-operative immunosuppressive and prophylactic treatment has been 
previously described (13, online supplementary). Concisely, all LTx recipients received triple-
drug immunosuppressive therapy with methylprednisolone, azathioprine (AZA) or 
mycophenolate mofetil (MMF) and cyclosporine A (CsA) or tacrolimus (FK). AR grade >A1 
was treated with intravenous pulse doses of methylprednisolone, tapered to the oral maintenance 
dose over the next 2-3 weeks, while A1 rejection was treated with augmenting oral steroids, 
similarly followed by tapering. Additionally, in case of recurrent AR, conversion from CsA to 
FK or from AZA to MMF was performed. There was no strict protocol for treatment of isolated 
grade B rejection, although most patients were treated similar to the protocol of grade A 
rejection by increasing steroids and/or changing immunosuppressives. Additionally, BOS ≥0-p 
was additionally treated with azithromycin and in case of progression with rapamycin, total 
lymph node irradiation or retransplantation. Initial infectious prophylaxis consisted of 
ganciclovir or acyclovir for CMV (depending on donor and recipient CMV status), inhaled 
amphotericin B for Aspergillus and long-term prophylaxis with sulfamethoxazole-trimethoprim 
for Pneumocystis.  
Statistical analysis 
For statistical analysis, every TBB specimen was regarded independently and investigated 
for concurrent clinical or BAL findings. Using Graphpad Prism 4.0 (San Diego, CA, USA), 
Wilcoxon signed rank test (online supplement), Mann-Whitney-U test or non-parametric 
Kruskall-Wallis with Dunn’s post-testing were performed where appropriate. Contingency tables 
were analyzed using Chi square test. Correlation between severity of histological grade on TBB 
(0 to 3) and various clinical and BAL parameters was assessed by Spearman rank test. Results of 
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the data are presented either as total values, mean (±standard deviation), median (with inter-
quartile range) or as percentages. A p-value of <0.05 was considered significant.  
 
Results 
The included patients’ characteristics are summarized in table 1. A total of 1984 
bronchoscopic procedures were performed in 339 LTx recipients, with a median of 6 (3-8) per 
patient and at a median of 182 (37-546) days after LTx. Subsequent TBB were performed in 832 
cases (59.4% as surveillance and 40.6% on clinical indication), with a median of 2 (1-3) TBB per 
patient performed at a median of 92 (32-367) days after LTx. After exclusion of 64 (7.7%) TBB 
with histological signs of concurrent bacterial/fungal or CMV-infection (14;15), a total of 768 
TBB with preceding BAL were included for the current analysis (Figure 1). Distribution of 
excluded and included TBB specimens according to A and B grading is presented in table 2. The 
yield of bronchoscopy to detect AR (grade A>0) or LB (grade B>0) in the included TBB 
specimens was respectively 28.6% (n=220/768) and 14.5% (n=111/768), which is within the 
previously reported range (16).  As only one TBB demonstrated grade A4B4 (severe) rejection, 
this sample was not included for further analyses.  
When histological grade A or B severity scores (0-3, excluding x) were correlated with 
concurrent clinical and BAL findings, not only an association between grade A and B severity 
scores could be demonstrated (r=0.20, p<0.0001), but also between the grade A, respectively B, 
severity score and other relevant parameters (table 3). Grade A severity, for instance, was 
inversely related with FEV1 (% predicted), whereas for grade B severity no association was seen. 
On the other hand, grade B severity correlated with time of TBB sampling after LTx, whereas for 
grade A no association was present (table 3). Neither increasing grade A nor grade B severity was 
associated with the volume of BAL fluid return; however, both did correlate with BAL total cell 
count. Higher grade A, but not B, severity scores were associated with elevated BAL lymphocyte 
percentages (table 3). Particularly BAL CD8
+ 
T-cells tended to be associated with higher grade A 
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severity (r=0.15, p=0.08), whereas no correlation was seen with either BAL B-cells or CD4
+ 
T-
cells (p=0.30 and p=0.12 respectively). Both higher grade A and B severity correlated with 
increased BAL neutrophil percentages (table 3). As expected by the increase in neutrophils and 
lymphocytes, macrophage percentages were inversely associated both with higher grade A or B 
severity. Eosinophilia, on the other hand, was associated with grade A, but not B, severity (table 
3). IL-6 levels tended to be associated with grade A severity, but not with grade B severity, 
whereas IL-8 levels correlated with both. TGF-ß protein levels, on the other hand, were inversely 
related with grade A severity and tended to be directly associated with higher B-grade severity 
(table 3). No correlation whatsoever was seen between severity of histological A or B grade and 
either the presence of gram-negative or –positive bacteria in BAL, or concurrent azithromycin-
use at the time of sampling (table 3). Reanalysis after excluding TBB with concurrent 
azithromycin-use (n=120/768, 15.6%) revealed similar significant associations (data not shown).  
Because Ax and Bx TBB samples were not included in correlation-analyses with grade A or 
B severity scores (i.e. 0-3); variations between different grade A severity scores (regardless of 
concurrent grade B severity: A0-3B0/1/2/3/x), or between grade B severity scores (regardless of 
concurrent grade A severity: B0-3A0/1/2/3/x) respectively, were additionally analyzed and 
summarized in table 4 and figure 2. Similar associations between increasing grade A (regardless 
of grade B) or B (regardless of grade A) severity scores and the various clinical and BAL cellular 
characteristics mentioned before were seen when taking Bx, respectively Ax, samples into 
account (table 4, figure 2).  
Next, excluding a possible confounding effect of concurrent grade B or A rejection, 
subanalysis of BAL total cell count and cell differentials (neutrophilia and lymphocytosis) was 
performed for each grade A (A0/1/2/3/x) in absence of concurrent grade B rejection (B0) and for 
each grade B (B0/1/2/3/x) in absence of concurrent grade A rejection (A0) respectively (Table 4, 
first column, figure 3A). Within both groups (i.e. A0B0/1/2/3/x, B0/A0/1/2/3/x) a similar pattern 
regarding BAL total cells, neutrophilia and lymphocytosis could be demonstrated with increasing 
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grade B, respectively A severity (figure 3A). The observed cellular differences again were 
independent form the presence of gram-negative or -positive bacteria in BAL or concurrent 
azithromycin-use at the time of sampling (figure 3A). Furthermore, BAL neutrophilia tended to 
be more severe in the higher B when compared to A grades (A0B1 vs. A1B0 p=0.05, A0B2 vs. 
A2B0 p=0.07 and A0B3 vs. A3B0 p=0.08 respectively), whilst for lymphocytosis a similar 
pattern (however also not statistically significantly different) was seen for the highest A 
compared to B grades (figure 3B).  
While assessing the aforementioned data, we additionally identified a historical cohort of 8 
LTx recipients in whom LB was diagnosed without concurrent grade A-rejection, signs of 
infection or OB/BOS and who (all except one) initially had been treated by augmenting steroids, 
yet because of unsatisfactory FEV1-recovery soon thereafter were empirically started on 
azithromycin (figure 3, online supplement). Despite the fact of being a historical cohort and 
lacking placebo-treated controls, the additional significant improvement in FEV1 and decrease in 
BAL neutrophilia observed in these patients thereafter were at least impressive especially when 
compared with a matched, azithromycin-naïve cohort (figure in online supplement). 
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Discussion 
This is the first study to date demonstrating a direct relationship between BAL cellular and 
protein characteristics with the severity of either grade A and B rejection score of concurrent 
TBB specimens. Increasing grade A severity (regardless of concurrent grade B severity) was 
associated both with an increase of BAL lymphocytosis and to a lesser extent neutrophilia, 
whereas for the higher B grades (regardless of concurrent grade A severity) particularly marked 
neutrophilia was present. IL-8 protein levels showed a similar association with both grade A or B 
severity. A similar trend was seen for IL-6 with grade A and for TGF-ß with grade B severity. 
Furthermore, even in absence of concurrent grade B rejection, grade A severity seems to be 
associated with BAL lymphocytosis, as previously demonstrated (6), whereas grade B severity in 
absence of concurrent grade A rejection is more related to BAL neutrophilia, as was already 
suggested by Zheng et al. (7). The current data may also confirm the previous report by Tikkanen 
et al. demonstrating increased proportions of BAL lymphocytes in ‘early’ versus neutrophils in 
‘later’ (i.e. >180 days post-LTx) occurring rejection, although their use of a semi-quantitative 
scoring system of TBB specimens makes it impossible to know whether the latter condition 
specifically corresponds with B grades or the more severe rejections of the present ISHLT 
scoring system in general (15). Similarly, a recent gene expression study of BAL cells in acute 
rejection (defined as a combined A+B score ≥2) by Patil et al. demonstrated an increase of both 
BAL lymphocyte and particularly neutrophil percentages with increasing probability of rejection 
(generated by means of ‘prediction analysis of microarrays’ based on BAL gene expression 
profile) (17). Yet again, merging histological grade A and B scores results in a less specific 
scoring; which in fact makes it impossible to assess BAL cellularity according to separate grade 
A or B severity scores, as was performed in our study.  Nevertheless, our data, together with that 
of the above-mentioned groups, are corroborated by a recent study in renal transplant recipients 
demonstrating that biopsy specimens in acute rejection may reveal extensive differences in gene 
expression, which are compatible with different subtypes of acute rejection characterized by 
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differences in immunologic and cellular features, but also in clinical course (e.g. glucocorticoid 
resistance, graft loss) (18). The most striking observation in our study, however, may be the 
apparent paradox in histological and concurrent BAL findings in LB showing mononuclear 
lymphocytic cellular infiltrates in the airway wall on the one hand and a predominant luminal 
(BAL) neutrophilia on the other hand. Moreover, these findings were not only present in higher 
B-grades (B3/4 or B2R), in which some neutrophils may also be present within the biopsy 
specimen as stated in the revised ISHLT scoring system (2), but also in the lower grades (B1/2 or 
B1R), possibly indicating a specific characteristic of LB. As BAL samples and TBB represent 
cells from different compartments of the broncho-alveolar unit, some discrepancies between both 
may be present due to different biological events in the airway lumen compared to the wall, but it 
seems highly unlikely this can explain the observed differences in cellularity and protein levels 
between various grade A or B severities.    
Despite the fact that LB was already recognized in pulmonary allografts almost two decades 
ago (9), its importance was left for a long time undetermined in the ISHLT allograft rejection 
working formulation (10). Moreover, its definition has considerably changed with successive 
revisions of the ISHLT classification, further obscuring assessment of its significance after LTx 
(2). In recent years, however, it has become clear that LB is an independent risk factor for 
subsequent development of BOS (19), which interestingly even seems to be directly related to the 
severity of LB (3;4). Since BAL neutrophilia is considered as a hallmark of the azithromycin-
responsive phenotype of BOS (20), together with both the fact that LB seems to appear later after 
LTx (21) and that increasing severity of LB is associated with more pronounced BAL 
neutrophilia (as shown herein), one could question the current dogma of LB being a marker of 
‘acute’ allograft rejection. It may therefore perhaps be more appropriate to be considered as an 
early stage in the evolution of chronic allograft dysfunction, in particular the neutrophilic 
reversible allograft dysfunction BOS-phenotype.  
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As clinical diagnosis is often difficult, due to confounding (or even little or no) symptoms, 
various or non-specific radiographic abnormalities and inconsistent spirometric results, many 
centers have implemented surveillance bronchoscopy with TBB (despite its rather low diagnostic 
yield) and institute pre-emptive therapy for AR and LB, hoping to prevent evolution to chronic 
rejection. Yet, both histological and associated pulmonary function changes in either condition 
may be refractory to treatment, in particular corticosteroids, suggesting that perhaps also 
alternative therapies should be implemented (3;9;22). Therefore, keeping the current results in 
mind, ‘tailored treatment’ may be more appropriate by adding azithromycin in those cases 
expressing an increased BAL neutrophilia versus steroids alone for those with a predominant 
lymphocytosis. Although the anti-inflammatory and anti-oxidative effects of macrolides have 
been well established in patients with BOS since their introduction in the field of LTx, the 
potential benefit in AR or LB has thus far never been investigated. Yet, the subsequent evolution 
of FEV1 and BAL neutrophilia in the historical cohort additionally described in the online 
supplement supports the former hypothesis that, particularly in LB, adding azithromycin may be 
beneficial. These preliminary observations of course remain to be confirmed in a formal, 
prospective placebo-controlled study.  
Evidently, possible confounding factors need to be addressed concerning the current study. 
The main limitation of the present study remains it’s retrospective, cross-sectional and 
monocentric design, but it is strengthened by the large number of biopsies taken, as well as the 
constancy of examination and reporting by a single experienced transplant pathologist over a 7-
year period. However TBB specimens with obvious histological signs of infection were excluded 
for analysis, subclinical infection or airway colonization might nevertheless interfere with the 
interpretation of histological and concurrent BAL findings. Therefore, the presence of either 
Gram-negative or –positive bacteria in concomitant BAL fluid was also taken into account in the 
present study; which, however, could not explain the current findings. On the other hand, we 
acknowledge that reliance on BAL fluid cultures may not be that unfailing in immunosuppressed 
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LTx recipients because of the possibility of atypical or difficult-to-culture respiratory pathogens. 
Furthermore, it remains unclear whether the observed differences in BAL profile with increasing 
histological grade A or B severity may have been obscured by different immunosuppressives at 
the time of sampling (23). Next, as gastroesophageal reflux was not systematically assessed 
during the follow-up period of the studied cohort, its importance for BAL and histology could 
unfortunately not be investigated, as it has recently become increasingly obvious that reflux may 
be associated with airway inflammation (24). Finally, the presence of other interstitial lesions of 
the pulmonary graft, the role of the previously described TH17-lineage (11;25) or the assessment 
of patient survival and freedom from BOS according to preceding grade A or B-rejection scores 
were not within the scope of the present paper.  
 
In conclusion, this study is the first to demonstrate a direct association between the 
histological grade of either AR or LB with concomitant BAL cellular and protein characteristics. 
Higher grade A severity is mainly associated with increased BAL lymphocytosis, whereas both 
with increasing grade A, but particularly grade B, severity elevated BAL neutrophilia is present. 
Consequently, BAL findings may guide treatment, whereas specifically in LB there may be a 
benefit of additional azithromycin treatment (as is also suggested by the additional historical 
patient cohort in the online supplement). These preliminary observations, however, remain to be 
confirmed in a formal, prospective placebo-controlled study. 
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Tables 
Table 1: Included patients’ characteristics 
 
  LTx-procedures (n=351) 
Age at LTx (years) 52 (38-58) 
Gender (male/female) 189/162 
Type of LTx 
*
  
   BLTx 240 
   SLTx 89 
   HLTx 22 
Pre-LTx diagnosis  
   Emphysema (COPD)† 145 
   Pulmonary Fibrosis 64 
   Cystic Fibrosis 51 
   α1-antitrypsin deficiency 22 
   Pulmonary Arterial Hypertension 22 
   Eisenmenger syndrome 12 
   Obliterative bronchiolitis 15 
   Bronchiectasis 10 
   Lymphangioleiomytosis 3 
   Histiocytosis X 2 
   Kartagener syndrome 2 
   Miscellaneous 3 
Time of follow-up (years)          2.7 (1.3-5.4) 
 
 
Table 1 legend 
Characteristics for all included lung transplant (LTx) recipients (n=339), in whom 351 
transplantations were performed (including 12 re-LTx). Data are presented as total value or 
median (inter-quartile range).  
Abbreviations: 
*
BLTx: bilateral lung transplantation, SLTx: single lung transplantation, HLTx: 
heart-lung transplantation, †COPD: chronic obstructive pulmonary disease.  
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Table 2: Distribution of TBB specimens according to A and B grading 
 
Excluded, 
n (%) A0 A1 A2 A3 A4 Ax Total 
B0 36 (56.3) 3 (4.7) 4 (6.3) 1 (1.6) 0 2 (3.1) 46 (71.9) 
B1 2 (3.1) 0 0 0 0 0 2 (3.1) 
B2 2 (3.1) 0 0 0 0 1 (1.6) 3 (4.7) 
B3 1 (1.6) 0 1 (1.6) 0 0 0 2 (3.1) 
B4 0 0 0 0 0 0 0 
Bx 4 (6.3) 0 2 (3.1) 0 0 5 (7.8) 11 (17.2) 
Total 45 (70.3) 3 (4.7) 7 (10.9) 1 (1.6) 0 8 (12.5) 64 (100.0) 
        
        
        
Included,  
n (%) A0 A1 A2 A3 A4 Ax Total 
B0 383 (49.9) 80 (10.4) 44 (5.7) 13 (1.7) 0 32 (4.2) 552 (71.9) 
B1 31 (4.0) 16 (2.1) 12 (1.6) 2 (0.3) 0 3 (0.4) 64 (8.3) 
B2 16 (2.1) 3 (0.4) 9 (1.2) 1 (0.1) 0 2 (0.3) 31 (4.0) 
B3 6 (0.8) 2 (0.3) 2 (0.3) 3 (0.4) 0 2 (0.3) 15 (2.0) 
B4 0 0 0 0 1 (0.1) 0 1 (0.1) 
Bx 61 (7.9) 17 (2.2)  8 (1.0) 7 (0.9) 0 12 (1.6) 105 (13.7) 
Total 497 (64.7) 118 (15.4) 75 (9.8) 26 (3.4) 1 (0.1) 51 (6.6) 768 (100.0) 
 
 
Table 2 legend 
Distribution of excluded and included transbronchial biopsy (TBB) specimens according to A and 
B-grading (10). Data are presented as total value (percentage). 
 
Table 3: Correlation of grade A or B severity scores (0-3, excluding x) with concurrent 
clinical and BAL findings 
    A0-3 (n=716) B0-3 (n=662) 
    r p r p 
POD
 
(days)
* 
-0.06 0.10 0.09 0.02 
FEV1
 
(%pred)† -0.17 <0.0001 -0.04 0.39 
BAL Return (mL/100mL)‡
 
-0.05 0.22 -0.05 0.26 
 Total cells (x10³/mL) 0.16 <0.0001 0.21 <0.0001 
     Neutrophils (%) 0.18 <0.0001 0.27 <0.0001 
     Lymphocytes (%) 0.17 <0.0001 0.03 0.45 
     Macrophages (%) -0.24 <0.0001 -0.27 <0.0001 
     Eosinophils (%) 0.15 0.0001 0.01 0.96 
 IL-6 (pg/mL)§ 0.07 0.08 -0.05 0.22 
 IL-8 (pg/mL)§ 0.13 0.0008 0.08 0.04 
 TGF-β (pg/mL)ll -0.10 0.007 0.07 0.08 
 GN-culture positive, n (%)** -0.03 0.44 0.03 0.48 
 GP-culture positive, n (%)†† 0.02 0.68 0.01 0.75 
Azithromycin-use at TBB, n (%)‡‡ 0.04 0.31 0.04 0.35 
 
Table 3 legend 
Transbronchial biopsies (TBB) classified according to their histological grade (0=absent, 
1=minimal, 2=mild, 3=moderate, x=upgradeable) and subsequently compared for time of 
sampling, pre-bronchoscopy FEV1 and concurrent BAL cellular and cytokine-profiles.  
Ax (n=51/768 or 6.6%) and Bx (n=105/768 or 13.7%) TBB samples could not be included in 
correlation-analyses with grade A or B severity scores (0-3) and as only one TBB demonstrated 
grade A4B4 (severe) rejection, this sample was not included for analysis. Correlation coefficient r 
and p-value are given for non-parametric Spearman rank test.  
 
Abbreviations: 
*
POD=post-operative day after transplantation, †FEV1=forced expiratory volume 
in one second (% predicted), ‡BAL= broncho-alveolar lavage, §IL= interleukin, llTGF-β= 
transforming growth factor-β, **GN= Gram-negative, ††GP= Gram-positive, ‡‡Azithromycin= 
concurrent treatment with azithromycin at the moment of transbronchial biopsy (TBB).  
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Table 4: Demographical and BAL characteristics according to TBB grade A or B severity score 
    A0 B0/1/2/3/x A1 B0/1/2/3/x A2 B0/1/2/3/x A3 B0/1/2/3/x p Ax B0/1/2/3/x 
    n=497 n=118 n=75 n=26  n=51 
POD
 
(days)
* 
92.0 (37.0-376.5) 87.5 (26.5-403.5) 87.0 (24.0-278.0) 184.5 (36.0-444.5) 0.15 94.0 (92.0-645.0) 
FEV1
 
(%pred)† 65 (53-80) 59 (47-75) * 55 (43-70) *** 63 (44-79) 0.001 66 (50-86) 
BAL Return (mL/100mL)‡
 
40.0 (32.0-50.0) 43.0 (35.0-50.0) 38.0 (25.0-45.0) 36.0 (30.0-46.0) 0.06 42.0 (31.0-50.0) 
 Total cells (x10³/mL) 140.0 (65.0-303.0) 195.5 (95.0-411.5) * 200.0 (98.0-606.5) ** 288.5 (70.0-730.0) * 0.0005 133.0 (73.0-338.0) 
     Neutrophils (%) 5.0 (1.6-25.5) 6.2 (1.6-40.0) 24.0 (5.5-61.9) *** 27.8 (7.1-81.5) *** <0.0001 8.5 (1.4-49.5) 
     Lymphocytes (%) 3.6 (1.5-7.6) 4.5 (2.0-10.5) 6.0 (3.0-10.8) ** 6.2 (3.5-22.3) ** <0.0001 3.2 (1.6-7.6) 
     Macrophages (%) 86.6 (62.4-94.2) 82.0 (51.8-92.4) * 60.0 (27.4-81.8) *** 32.3 (10.3-78.0) *** <0.0001 81.4 (44.3-94.1) 
     Eosinophils (%) 0.0 (0.0-0.2) 0.0 (0.0-0.2) 0.0 (0.0-0.5) 0.7 (0.0-2.2) *** <0.0001 0.0 (0.0-0.5) 
 IL-6 (pg/mL)§ 0.4 (0.1-1.5) 0.4 (0.1-1.6) 0.5 (0.1-2.0) 0.8 (0.4-13.2) * 0.016 0.3 (0.1-1.6) 
 IL-8 (pg/mL)§ 42.5 (14.3-111.7) 46.7 (18.0-119.0) 94.2 (35.7-168.2) ** 113.9 (30.3-189.8) * 0.0009 43.7 (13.7-133.9) 
 TGF-β (pg/mL)ll 9.6 (2.5-117.8) 2.5 (2.5-63.7) 2.5 (2.5-68.2) 2.5 (2.5-68.5) 0.09 3.3 (2.5-115.0) 
 GN-culture positive, n (%)** 87 (17.5) 18 (15.3) 10 (13.3) 5 (19.2) 0.77 11 (21.6) 
 GP-culture positive, n (%)†† 40 (8.0) 8 (6.8) 9 (12.0) 2 (7.7) 0.64 3 (5.9) 
Azithromycin-use at TBB, n (%)‡‡ 71 (14.3) 22 (18.6) 8 (10.7) 8 (30.8) * 0.06 11 (21.6) 
    
      
    B0 A0/1/2/3/x B1 A0/1/2/3/x B2 A0/1/2/3/x B3 A0/1/2/3/x p Bx A0/1/2/3/x 
    n=552 n=64 n=31 n=15  n=105 
POD
 
(days)
* 
91.0 (30.5-339.0) 111.5 (27.0-657.5) 181.0 (72.0-538.0) 466.0 (179.0-997.0) *
 
0.009 91.0 (31.0-267.5) 
FEV1 (%pred)
† 63 (50-79) 60 (44-80) 68 (47-75) 61 (46-70) 0.83 65 (53-77) 
BAL Return (mL/100mL)‡ 41.0 (32.0-50.0) 40.0 (31.0-45.5) 40.5 (31.0-45.0) 36.5 (31.5-42.0) 0.35 40.0 (30.0-49.0) 
 Total cells (x10³/mL) 142.5 (69.0-298.0) 218.5 (90.0-440.0) 506.0 (185.0-865.0) *** 598.0 (232.0-1489.0) *** <0.0001 141.0 (70.0-350.0) 
     Neutrophils (%) 5.0 (1.6-25.1) 20.0 (3.3-60.5) ** 45.1 (12.2-76.2) *** 73.2 (42.6-83.6) *** <0.0001 6.8 (1.8-32.0) 
     Lymphocytes (%) 4.0 (1.6-8.0) 4.0 (2.0-10.4) 4.5 (1.8-9.6) 4.5 (2.1-12.0) 0.87 3.8 (1.6-8.4) 
     Macrophages (%) 86.2 (60.5-94.2) 72.0 (34.5-90.5) ** 40.7 (14.4-79.4) *** 21.8 (10.4-53.5) *** <0.0001 84.0 (51.0-92.7) 
     Eosinophils (%) 0.0 (0.0-0.2) 0.0 (0.0-0.2) 0.0 (0.0-1.1) 0.0 (0.0-1.0) 0.37 0.0 (0.0-0.3) 
 IL-6 (pg/mL)§
 
0.4 (0.1-1.6) 0.4 (0.1-1.6) 0.1 (0.1-1.4) 0.6 (0.1-2.2) 0.40 0.4 (0.1-1.5) 
 IL-8 (pg/mL)§ 42.8 (14.3-116.4) 52.9 (21.9-156.9) 80.8 (17.3-163.6) 74.6 (10.1-194.3) 0.22 51.2 (21.0-159.0) * 
 TGF-β (pg/mL)ll 2.5 (2.5-99.7) 25.2 (2.5-134.1) 5.8 (2.5-63.9) 57.3 (11.1-235.8) 0.07 2.5 (2.5-105.9) 
 GN-culture positive, n (%)** 94 (17.0) 10 (15.6) 6 (19.4) 5 (33.3) 0.24 16 (15.2) 
 GP-culture positive, n (%)†† 43 (7.8) 8 (12.5) 2 (6.5) 0 (0.0) 0.40 9 (8.6) 
Azithromycin-use at TBB, n (%)‡‡ 90 (16.3) 13 (20.3) 3 (9.7) 6 (40.0) 0.06 8 (7.6) 
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Table 4 legend 
Transbronchial biopsies (TBB) classified according to their histological grade (0=absent, 1=minimal, 
2=mild, 3=moderate, x=upgradeable) and subsequently compared for time of sampling, pre-
bronchoscopy FEV1 and concurrent BAL cellular and cytokine-profiles. As only one TBB 
demonstrated grade A4B4 (severe) rejection, this sample was not included for comparison.  
Variations between grades A0-3B0/1/2/3/x and B0-3A0/1/2/3/x respectively were calculated by non-
parametric Kruskall-Wallis test with Dunn’s multiple comparison test for post-testing (with 
significances compared to A0B0/1/2/3/x or B0A0/1/2/3/x respectively expressed as * p<0.05, **: 
p<0.01, ***: p<0.001). Chi-square test was used to compare proportions between groups. 
Additionally, the groups AxB0/1/2/3/x and BxA0/1/2/3/x were also compared with the group with 
the lowest histological A or B grade (A0B0/1/2/3x or B0A0/1/2/3/x respectively), significances were 
analyzed by Mann-Whitney test and expressed as *: p<0.05. Data are presented as median (inter-
quartile range).  
Note: 
-  BAL cell count and differentials (neutrophilia en lymphocytosis) between different groups are also 
presented in figure 2. 
- Data of the lowest histological A or B grade (A0B0/1/2/3x or B0A0/1/2/3/x respectively) within the 
first column were further analyzed for BAL cell count and differentials (neutrophilia and 
lymphocytosis) and are presented in figure 3A+B. 
Abbreviations: 
*
POD=post-operative day after transplantation, †FEV1=forced expiratory volume in 
one second (% predicted), ‡BAL= broncho-alveolar lavage, §IL= interleukin, llTGF-β= transforming 
growth factor-β, **GN= Gram-negative, ††GP= Gram-positive, ‡‡Azithromycin= concurrent treatment 
with azithromycin at the moment of transbronchial biopsy (TBB).  
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Figure Legends 
Figure 1: Study design 
Abbreviations: LTx=lung transplantation, TBB=transbronchial biopsy, BAL=broncho-alveolar 
lavage, CMV=cytomegalovirus, A=acute rejection and B=lymphocytic bronchiolitis (according to 
histological grade 0=absent, 1=minimal, 2=mild, 3=moderate, 4=severe, x=upgradeable). 
 
 
Figure 2: BAL cellular characteristics according to grade A or B severity score 
Transbronchial biopsies (TBB) were classified according to their histological grade (0=absent, 
1=minimal, 2=mild, 3=moderate, x=upgradeable) and subsequently compared for BAL cellular 
profiles. As only one TBB demonstrated grade A4B4 (severe) rejection, this sample was not included 
for comparison.  
Variations between grades A0-3B0/1/2/3/x, respectively B0-3A0/1/2/3/x, were calculated by non-
parametric Kruskall-Wallis test with Dunn’s post-testing (with significances compared to 
A0B0/1/2/3/x or B0A0/1/2/3/x respectively expressed as * p<0.05, **: p<0.01 or ***: p<0.001). Bars 
represent mean+SEM. 
Note: data of the lowest histological A or B grade (A0B0/1/2/3x or B0A0/1/2/3/x respectively) were 
further analyzed for BAL cell count and differentials (neutrophilia and lymphocytosis) and are 
presented in figure 3A+B. 
 
 
Figure 3: Subanalysis of BAL cellular characteristics according to grade A or B severity score 
Panel A (top): Transbronchial biopsies (TBB) were classified according to their histological grade 
(0=absent, 1=minimal, 2=mild, 3=moderate, x=upgradeable) and subsequently compared for BAL 
cellular profiles. As only one TBB demonstrated grade A4B4 (severe) rejection, this sample was not 
included for comparison.  
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Variations between grades A0B0/1/2/3 or B0A0/1/2/3 respectively were calculated by non-
parametric Kruskall-Wallis test with Dunn’s post-testing (with significances compared to A0B0 or 
B0A0 respectively expressed as * p<0.05, **: p<0.01 or ***: p<0.001). Bars represent mean+SEM. 
Abbreviations: BAL=broncho-alveolar lavage, GN=presence of Gram-negative bacteria in BAL (n-
value or %), GP=presence of Gram-positive bacteria in BAL (n-value or %), AZI=concurrent 
treatment with azithromycin at the moment of transbronchial biopsy (TBB) (n-value or %).  
 
Panel B (bottom): Comparison of BAL neutrophilia and lymphocytosis according to histological A 
or B severity grade, in absence of concurrent grade B or A rejection respectively. Differences 
between grades (A0B1 vs. B0A1, A0B2 vs. B0A2 and A0B3 vs. B0A3) were analyzed by Mann-
Whitney test and p<0.05 was considered significant. Data are represented as mean+SEM.  
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Figures 
 
Figure 1 
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Figure 2 
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Figure 3 
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Supplementary material 
FEV1 and BAL neutrophilia in two matched historical patient cohorts 
 Lymphocytic bronchiolitis (A0B1 n=3, A0B2 n=2, A0B3 n=3; without signs of infection 
or OB/BOS) was diagnosed on transbronchial biopsies (TBB) at a median of 115 (68-631) 
days after LTx in 8 LTx recipients (Single (S) LTx =n1, Bilateral (B) LTx n=7) (panel A). 
Mean BAL neutrophilia at TBB was 68.0±20.4% (n=8), one BAL sample was colonized with 
P. aeruginosa and one with S marcescens.  
 One patient (A0B1) received no subsequent treatment, whilst the other were treated with 
augmenting methylprednisolone (IV 3x500mg/d n=6 or PO 3x48mg/d n=1, followed by 
tapering). Because of persistent dyspnea, coarse crackles on auscultation and insufficient 
improvement of FEV1 (mean 5.5±6.1% or 190±224mL, p=0.11) at re-evaluation 11 (10-19) 
days after TBB, azithromycin (AZI) was associated (250 mg/2d) after which FEV1 further 
significantly improved with 13.5±7.4% or 414±236mL (p=0.008) (panel B) and BAL 
neutrophilia decreased to 13.7 (±11.7)% (n=6, p=0.03) 3 months (mo.) later (panel C). In a 
matched, historical patient-cohort (similar age, type of LTx, timing and grade of TBB; p-
value calculated by χ² or Mann-Whitney-U test; panel A), of which all but one were similarly 
treated by augmenting methylprednisolone at the time of TBB (IV n=6, PO n=1), but none 
with subsequent azithromycin, a lesser (however not statistically significant) improvement in 
FEV1 and decrease in BAL neutrophilia was seen.  
 Data in graph are expressed as mean±SEM, * p<0.05, ** p<0.01 (Wilcoxon Signed Rank 
test vs. start of AZI for FEV1 or vs. BAL at TBB for cell counts). 
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Online supplement Figure  
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